ARK Investment Management Adds $4M in Intellia Therapeutics, Inc. ($NTLA)
ARK Investment Management increased its holdings in Intellia Therapeutics by 301,923 shares, reflecting a 2.1% rise.
Key Points
- ARK Investment Management boosted its stake in Intellia Therapeutics by 301,923 shares, reaching 14.5 million shares valued at $175.6 million.
- Shares of Intellia Therapeutics traded around $12.10, with a market cap of $1.69 billion and a 52-week range of $7.95 to $28.25.
- Insiders at Intellia Therapeutics, including Fred Cohen and William Chase, purchased shares on June 9, 2026.
ARK Investment Management has increased its stake in Intellia Therapeutics, Inc. (NasdaqGM: NTLA) by 301,923 shares, bringing its total holdings to about 14.5 million shares. This move, reported in the latest Form 13F filing with the SEC, represents a 2.1% increase in their position, now valued at approximately $175.6 million as of the end of the reporting period.
What Changed in ARK Investment Management's Intellia Therapeutics Position
ARK Investment Management's recent filing shows a boost in its Intellia Therapeutics holdings from 14.2 million shares to roughly 14.5 million shares, an increase of 301,923 shares. The value of this increased stake is approximately $175.6 million, reflecting a 2.1% rise in their investment.
Other Institutional Activity in Intellia Therapeutics
In addition to ARK Investment Management, BlackRock, Inc. increased its holdings by 1,878,957 shares, ending with 12.2 million shares valued at about $155.8 million. State Street Corp added 503,840 shares, bringing its total to 6.9 million shares worth approximately $88.7 million. D. E. Shaw & Co., Inc. also grew its position by 397,113 shares, reaching a total of 5.7 million shares valued at $73.4 million.
Intellia Therapeutics Stock Snapshot
Shares of Intellia Therapeutics traded near $12.10. The company has a market cap of $1.69 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's 52-week range is from $7.95 to $28.25, with a 50-day moving average of $13.63 and a 200-day moving average of $13.39. Intellia's beta is 1.815, indicating higher volatility compared to the market.
Recent Earnings
Intellia Therapeutics reported revenue of $66.1 million, though it faced a revenue decline of 9.5% from the previous year. The company is not currently profitable, with an EPS of -$3.52 and a return on equity of -56.3%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Intellia Therapeutics, Inc.
Several insiders at Intellia Therapeutics, including Fred Cohen, William Chase, and Brian Goff, purchased shares on June 9, 2026. Each insider bought shares, though the exact values were not disclosed.
Analysts Set New Price Targets
On May 12, 2026, Canaccord Genuity maintained its buy rating on Intellia Therapeutics with a price target of $49. Wedbush reiterated a hold rating with a $12 target on the same date. Overall, the consensus among 19 analysts is to buy, with a mean price target of $26.63.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotech company based in Cambridge, Massachusetts, specializing in genome editing using CRISPR/Cas9 technology. The company is working on therapies for diseases like transthyretin amyloidosis and hereditary angioedema. Intellia collaborates with various partners to develop treatments for cancer and autoimmune diseases.
Bottom Line
ARK Investment Management's decision to increase its stake in Intellia Therapeutics signals continued interest in the company's potential. Investors often track such filings to gauge fund managers' confidence in a stock. It's important to remember that 13F filings are snapshots of past positions and may not reflect current holdings.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.